- Home
- ALDX vs EDIT Comparison
ALDX vs EDIT Comparison
Compare ALDX & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALDX
- EDIT
- Stock Information
- Founded
- ALDX 2004
- EDIT 2013
- Country
- ALDX United States
- EDIT United States
- Employees
- ALDX N/A
- EDIT N/A
- Industry
- ALDX Biotechnology: Pharmaceutical Preparations
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ALDX Health Care
- EDIT Health Care
- Exchange
- ALDX Nasdaq
- EDIT Nasdaq
- Market Cap
- ALDX 326.6M
- EDIT 263.7M
- IPO Year
- ALDX 2014
- EDIT 2016
- Fundamental
- Price
- ALDX $5.81
- EDIT $2.80
- Analyst Decision
- ALDX Strong Buy
- EDIT Buy
- Analyst Count
- ALDX 2
- EDIT 12
- Target Price
- ALDX $9.50
- EDIT $5.40
- AVG Volume (30 Days)
- ALDX 917.6K
- EDIT 2.1M
- Earning Date
- ALDX 08-07-2025
- EDIT 08-12-2025
- Dividend Yield
- ALDX N/A
- EDIT N/A
- EPS Growth
- ALDX N/A
- EDIT N/A
- EPS
- ALDX N/A
- EDIT N/A
- Revenue
- ALDX N/A
- EDIT $38,901,000.00
- Revenue This Year
- ALDX N/A
- EDIT N/A
- Revenue Next Year
- ALDX $29.89
- EDIT N/A
- P/E Ratio
- ALDX N/A
- EDIT N/A
- Revenue Growth
- ALDX N/A
- EDIT N/A
- 52 Week Low
- ALDX $1.14
- EDIT $0.91
- 52 Week High
- ALDX $7.20
- EDIT $4.12
- Technical
- Relative Strength Index (RSI)
- ALDX 71.16
- EDIT 53.45
- Support Level
- ALDX $5.34
- EDIT $2.60
- Resistance Level
- ALDX $5.73
- EDIT $3.17
- Average True Range (ATR)
- ALDX 0.27
- EDIT 0.23
- MACD
- ALDX 0.01
- EDIT 0.01
- Stochastic Oscillator
- ALDX 77.36
- EDIT 66.36
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.